Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage

TY - JOUR

T1 - Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage

AU - Bejder, Jacob

AU - Aachmann-Andersen, Niels Jacob

AU - Bonne, Thomas Christian

AU - Olsen, Niels Vidiendal

AU - Nordsborg, Nikolai Baastrup

N1 - CURIS 2016 NEXS 276

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The sensitivity of the adaptive model of the Athlete Biological Passport (ABP) and reticulocyte percentage (ret%) in detection of recombinant human erythropoietin (rHuEPO) misuse was evaluated using both a long-term normal dose and a brief high dose treatment regime. Sixteen subjects received either 65IU rHuEPO×kg-1 every second day for two weeks (normal-dose), 390IU rHuEPO×kg-1 on three consecutive days (high-dose), or frequent placebo treatment for 13days in a randomized, placebo-controlled, double-blind crossover design. Blood variables were measured 4, 11, and 25days following treatment initiation. The ABP based on haemoglobin concentration ([Hb]) and OFF-hr score ([Hb] - 60×√ret%) yielded atypical profiles following both normal-dose and high-dose treatment (0 %, 31 %, 13 % vs. 21 %, 33 %, 20 % at days 4, 11, and 25 after normal and high dose, respectively). Including ret% as a stand-alone marker for atypical blood profiles increased (P<0.05) the sensitivity of the adaptive model at day 11 to 63 % and 67 % for normal-dose and high-dose rHuEPO administration, respectively. In conclusion, ~30 % of subjects injecting a normal-dose rHuEPO for two weeks or a high-dose rHuEPO for three days will present an atypical ABP profile. Including ret% as a stand-alone parameter improves the sensitivity two-fold.

AB - The sensitivity of the adaptive model of the Athlete Biological Passport (ABP) and reticulocyte percentage (ret%) in detection of recombinant human erythropoietin (rHuEPO) misuse was evaluated using both a long-term normal dose and a brief high dose treatment regime. Sixteen subjects received either 65IU rHuEPO×kg-1 every second day for two weeks (normal-dose), 390IU rHuEPO×kg-1 on three consecutive days (high-dose), or frequent placebo treatment for 13days in a randomized, placebo-controlled, double-blind crossover design. Blood variables were measured 4, 11, and 25days following treatment initiation. The ABP based on haemoglobin concentration ([Hb]) and OFF-hr score ([Hb] - 60×√ret%) yielded atypical profiles following both normal-dose and high-dose treatment (0 %, 31 %, 13 % vs. 21 %, 33 %, 20 % at days 4, 11, and 25 after normal and high dose, respectively). Including ret% as a stand-alone marker for atypical blood profiles increased (P<0.05) the sensitivity of the adaptive model at day 11 to 63 % and 67 % for normal-dose and high-dose rHuEPO administration, respectively. In conclusion, ~30 % of subjects injecting a normal-dose rHuEPO for two weeks or a high-dose rHuEPO for three days will present an atypical ABP profile. Including ret% as a stand-alone parameter improves the sensitivity two-fold.

KW - Blood manipulation

KW - Doping control

KW - Recombinant human erythropoietin

U2 - 10.1002/dta.1932

DO - 10.1002/dta.1932

M3 - Journal article

C2 - 27696774

AN - SCOPUS:84952361635

SN - 1942-7603

VL - 8

SP - 1049

EP - 1055

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

IS - 10

ER -